Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.61 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.60 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.60 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7096653 | 0.91 | EPHX2 (0.59) | EPHX2TPSAB1TPSD1TPSG1ALDH1A1 | |
| SCHEMBL13873498 | 0.91 | EPHX2 (0.64) | EPHX2ALDH1A1TSHRCHRNA7SMN1; SMN2 | |
| SCHEMBL13890321 | 0.89 | EPHX2 (0.59) | EPHX2TPSAB1TPSD1TPSG1ALDH1A1 | |
| SCHEMBL4101221 | 0.89 | EPHX2 (0.61) | EPHX2ALDH1A1TSHRCHRNA7SMN1; SMN2 | |
| SCHEMBL4105262 | 0.89 | CHRNA7 (0.66) | EPHX2ALDH1A1TSHRCHRNA7SMN1; SMN2 | |
| SCHEMBL7092551 | 0.85 | EPHX2 (0.57) | EPHX2ALDH1A1TSHRCHRNA7SMN1; SMN2 | |
| SCHEMBL4114824 | 0.84 | EPHX2 (0.70) | EPHX2ALDH1A1TSHRCHRNA7ADRB2 | |
| SCHEMBL13873470 | 0.83 | EPHX2 (0.60) | EPHX2ALDH1A1TSHRCHRNA7SMN1; SMN2 | |
| SCHEMBL4106438 | 0.83 | EPHX2 (0.60) | EPHX2ALDH1A1TSHRCHRNA7SMN1; SMN2 | |
| SCHEMBL13873500 | 0.82 | EPHX2 (0.61) | EPHX2ALDH1A1TSHRCHRNA7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130324556-A1 | Protease Activated Receptor 2 (PAR2) Antagonists | PROXIMAGEN LTD. (GB) | 2013-12-05 | — | — | US | claimed |
| EP-2668157-A1 | PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS | Proximagen Limited (GB) | 2013-12-04 | — | — | EP | claimed |
| WO-2012101453-A1 | PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS | PROXIMAGEN LTD. (GB) | 2012-08-02 | — | — | WO | claimed |
| US-20130324556-A1 | Protease Activated Receptor 2 (PAR2) Antagonists | PROXIMAGEN LTD. (GB) | 2013-12-05 | — | — | US | disclosed |
| EP-2668157-A1 | PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS | Proximagen Limited (GB) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012101453-A1 | PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS | PROXIMAGEN LTD. (GB) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324556-A1 | Protease Activated Receptor 2 (PAR2) Antagonists | F2RL1, F2R, F2RL3 | EPHX2 2270/4885TPSAB1 169/4885TPSD1 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.